全文获取类型
收费全文 | 16583篇 |
免费 | 1343篇 |
国内免费 | 474篇 |
专业分类
耳鼻咽喉 | 74篇 |
儿科学 | 175篇 |
妇产科学 | 182篇 |
基础医学 | 1104篇 |
口腔科学 | 155篇 |
临床医学 | 1319篇 |
内科学 | 3942篇 |
皮肤病学 | 283篇 |
神经病学 | 891篇 |
特种医学 | 112篇 |
外国民族医学 | 1篇 |
外科学 | 1424篇 |
综合类 | 955篇 |
现状与发展 | 2篇 |
预防医学 | 311篇 |
眼科学 | 193篇 |
药学 | 4669篇 |
6篇 | |
中国医学 | 167篇 |
肿瘤学 | 2435篇 |
出版年
2024年 | 38篇 |
2023年 | 425篇 |
2022年 | 662篇 |
2021年 | 834篇 |
2020年 | 785篇 |
2019年 | 698篇 |
2018年 | 626篇 |
2017年 | 723篇 |
2016年 | 678篇 |
2015年 | 728篇 |
2014年 | 877篇 |
2013年 | 2039篇 |
2012年 | 765篇 |
2011年 | 926篇 |
2010年 | 682篇 |
2009年 | 731篇 |
2008年 | 735篇 |
2007年 | 667篇 |
2006年 | 649篇 |
2005年 | 524篇 |
2004年 | 433篇 |
2003年 | 388篇 |
2002年 | 363篇 |
2001年 | 263篇 |
2000年 | 218篇 |
1999年 | 187篇 |
1998年 | 198篇 |
1997年 | 163篇 |
1996年 | 144篇 |
1995年 | 128篇 |
1994年 | 114篇 |
1993年 | 102篇 |
1992年 | 97篇 |
1991年 | 83篇 |
1990年 | 77篇 |
1989年 | 72篇 |
1988年 | 50篇 |
1987年 | 68篇 |
1986年 | 43篇 |
1985年 | 61篇 |
1984年 | 57篇 |
1983年 | 39篇 |
1982年 | 52篇 |
1981年 | 33篇 |
1980年 | 35篇 |
1979年 | 34篇 |
1978年 | 35篇 |
1977年 | 20篇 |
1976年 | 18篇 |
1973年 | 9篇 |
排序方式: 共有10000条查询结果,搜索用时 218 毫秒
11.
12.
Ramya Deepthi Vinnakota Allan S. Brett 《The American journal of the medical sciences》2019,357(2):160-163
Iron deficiency anemia is often listed among potential adverse effects of gastric acid-suppressive medications, given that gastric acidity promotes intestinal absorption of nonheme iron. Additionally, the antacid calcium carbonate can inhibit iron absorption. However, there is little direct clinical evidence that proton-pump inhibitors, histamine-2 receptor antagonists, or calcium carbonate cause iron deficiency anemia. Most case reports have had substantial limitations (e.g., minimal follow-up and presence of other causes of iron deficiency), and retrospective cohort studies have lacked sufficient patient-specific detail to make strong causal inferences. We present 2 cases—both with detailed, prospective 10-year follow-up—in which combinations of proton-pump inhibitors, histamine-2 receptor antagonists and calcium carbonate were clearly associated with development of iron deficiency anemia. Overt iron-deficiency anemia is probably uncommon in patients who use acid-modifying medications and who have no other conditions that predispose to iron deficiency. Nevertheless, clinicians should be aware of this potential complication, given widespread use of these agents. 相似文献
13.
《The Journal for Nurse Practitioners》2022,18(8):910-914
This is a case study of a 73-year-old woman recently diagnosed with Alzheimer disease living in an assisted living facility who presented to an outpatient behavioral health clinic with her son for evaluation and treatment of depression. This article highlights the presentation of depression (a diagnosis) versus apathy (a symptom of Alzheimer disease) and the need to assess for co-occurring mood disorders that warrant pharmacologic intervention as well as treatment for cognitive decline in Alzheimer disease. 相似文献
14.
15.
《Clinical Lymphoma, Myeloma & Leukemia》2020,20(7):415-421
Myelofibrosis (MF) is a BCR-ABL1− myeloproliferative neoplasm that arises from hematopoietic stem and progenitor cells frequently harboring a somatic driver mutation in 1 of 3 genes: JAK2, CALR, or MPL. The pathologic features of this hematologic malignancy include myeloproliferation, diffuse bone marrow fibrosis, and overactivation of the JAK-STAT pathway, resulting in enhanced inflammatory cytokine release. The common clinical manifestations of MF include systemic symptoms, abnormal peripheral blood count levels, and splenomegaly. However, it has become increasingly appreciated that significant clinical heterogeneity exists among patients with MF. Two distinct MF clinical phenotypes include the myeloproliferative and myelodepletive phenotype, with peripheral blood counts being the main discerning feature. Patients with the myeloproliferative phenotype will present with elevated peripheral blood counts and often experience significant constitutional symptoms and progressive splenomegaly. In contrast, patients with the myelodepletive phenotype will have low peripheral blood counts and will frequently require transfusion support. Current frontline therapies for MF, include ruxolitinib and fedratinib, which can exacerbate cytopenias and thereby pose an impediment to effective treatment of the myelodepletive patient. The present review discusses the clinical and prognostic implications of the myelodepletive phenotype and the therapeutic options and limitations for this subset of patients, representing an unmet clinical need. 相似文献
16.
肝内胆管癌(ICC)可切除率低,进展期ICC的治疗有效率不高,预后很差。转化治疗在多种晚期肿瘤中有一定的疗效,是目前晚期肿瘤治疗的研究热点。随着对ICC基因组的深入了解和新的治疗药物的开发及组合,基于系统化疗的联合治疗策略,精准靶向治疗,免疫检查点抑制剂等显示出较好的疗效,使得部分进展期ICC病人能降期转化手术,获得长期生存。 相似文献
17.
《药学学报(英文版)》2020,10(7):1294-1308
A great challenge in multi-targeting drug discovery is to identify drug-like lead compounds with therapeutic advantages over single target inhibitors and drug combinations. Inspired by our previous efforts in designing antitumor evodiamine derivatives, herein selective histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) dual inhibitors were successfully identified, which showed potent in vitro and in vivo antitumor potency. Particularly, compound 30a was orally active and possessed excellent in vivo antitumor activity in the HCT116 xenograft model (TGI = 75.2%, 150 mg/kg, p.o.) without significant toxicity, which was more potent than HDAC inhibitor vorinostat, TOP inhibitor evodiamine and their combination. Taken together, this study highlights the therapeutic advantages of evodiamine-based HDAC1/TOP2 dual inhibitors and provides valuable leads for the development of novel multi-targeting antitumor agents. 相似文献
18.
Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) are a new type of drug for the treatment of diabetes, and they have been proven to have a good hypoglycemic effect. Several lines of clinical evidence have shown that SGLT2 inhibitors can significantly reduce the risks of atherosclerosis, hospitalization for heart failure, cardiovascular death, and all-cause mortality and delay the progression of chronic kidney disease. Because of the protective effects of SGLT2 inhibitors on the heart and kidney, they are being studied for the treatment of heart failure and chronic kidney disease in patients without diabetes. Therefore, it is necessary for cardiologists, patients with diabetes, and nephrologists to fully understand this type of drug. In this review, we summarize the following three aspects of SGLT2 inhibitors: the recent clinical evidence of their cardiovascular benefits, their mechanisms of action, and their safety. 相似文献
19.
You-Wen Tan 《World Journal of Meta-Analysis》2021,9(6):488-495
Nilotinib is a specific breakpoint cluster region-Abelson leukemia virus-tyrosine kinase inhibitor that is used as an effective first- or second-line treatment in imatinib-resistant chronic myelogenous leukemia (CML) patients. Hepatotoxicity due to nilotinib is a commonly reported side effect; however, abnormal liver function test (LFT) results have been reported in asymptomatic cases. When alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels are more than five-fold the upper limit of the normal (ULN) or when the serum total bilirubin level is more than three-fold the ULN, dose modification or discontinuation of nilotinib is recommended, resulting in decreased levels of hematological indicators in certain patients with CML. Nilotinib-induced hyperbilirubinemia typically manifests as indirect bilirubinemia without elevated ALT or AST levels. Such abnormal liver functioning is thus not attributed to the presence of a true histologic lesion of the liver. The underlying mechanism may be related to the inhibition of uridine diphosphate glucuronosyltransferase activity. Therefore, nilotinib dose adjustment is not recommended for this type of hyperbilirubinemia, and in the absence of elevated liver enzyme levels or presence of abnormal LFT findings, physicians should consider maintaining nilotinib dose intensity without modifications. 相似文献
20.
Wilbert S Aronow 《Expert opinion on pharmacotherapy》2016,17(2):205-215
Introduction: It is important to know how to treat hypertension in patients with coronary artery disease (CAD). The reason for the review was to update this treatment and to discuss the 2015 American Heart Association/American College of Cardiology/American Society of Hypertension 2015 guidelines of treatment of hypertension in patients with CAD.Areas covered: Studies between 1968 and 2015 were reviewed on treatment of hypertension in patients with CAD using a Medline search, and studies between 1977 and 2015 were reported. Hypertension should be treated with beta blockers and ACE inhibitors or angiotensin receptor blockers (ARBs). Long-acting nitrates are effective antianginal and anti-ischemic drugs. Calcium-channel blockers (CCBs) may be added if angina persists despite beta blockers and long-acting nitrates. The 2015 guidelines recommend that the blood pressure should be < 140/90 mm Hg in patients aged ≤ 80 years and the systolic blood pressure < 150 mm Hg if they are ≥ 80 years.Expert opinion: Hypertension in patients with CAD should be treated with beta blockers and ACE inhibitors or ARBs. Long-acting nitrates are effective antianginal and anti-ischemic drugs. CCBs may be added if angina persists despite beta blockers and long-acting nitrates. The blood pressure should be < 140/90 mm Hg in patients aged < 80 years and the systolic blood pressure < 150 mm Hg if they are ≥ 80 years. 相似文献